Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma

Table 3 Univariate analysis of predictors of survival after initial diagnosis of extrahepatic metastases in 151 patients

Variable	Hazard Ratio	95% CI	P
PS (0 vs 1-4)	2.181	1.50-3.17	< 0.001
Age ( ≤ 65 vs > 65 yr)	0.988	0.97-1.0	0.18
Sex (M vs F)	0.889	0.57-1.38	0.601
Child Pugh stage (A vs B, C)	2.323	1.73-3.12	< 0.001
Intrahepatic main tumor size ( ≤ 50 vs > 50 mm)	2.321	1.52-3.54	< 0.001
Intrahepatic tumor volume ( ≤ 50 vs > 50%)	2.523	1.71-3.72	< 0.001
Intrahepatic tumor morphology (nodular vs non nodular)	1.506	1.04-2.18	0.03
Vp (0-2 vs 3, 4)	2.247	1.53-3.29	< 0.001
AFP ( ≤ 400 vs > 400 ng/mL)	1.158	0.80-1.68	0.439
DCP ( ≤ 1000 vs > 1000 mAU/mL)	1.584	1.08-2.33	0.02
Treatment (performed vs not performed)1	2.385	1.51-3.77	< 0.001
Site (lung vs others)2	1.065	0.74-1.52	0.731
Site (bone vs others)	1.61	1.11-2.33	0.012
Site (only lymph node vs others)	1.133	0.74-1.74	0.567

¹Treatments: various treatments for extrahepatic metastases (surgical resection, TACE, systemic chemotherapy and/or radiotherapy);

²Site: site of extrahepatic metastases.